Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice.

Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H.

Endocrinology. 2013 Dec;154(12):4503-11. doi: 10.1210/en.2013-1666. Epub 2013 Oct 3.

PMID:
24092637
[PubMed - indexed for MEDLINE]
2.

Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.

Romaní-Pérez M, Outeiriño-Iglesias V, Gil-Lozano M, González-Matías LC, Mallo F, Vigo E.

Endocrinology. 2013 Mar;154(3):1144-55. doi: 10.1210/en.2012-1786. Epub 2013 Jan 25.

PMID:
23354098
[PubMed - indexed for MEDLINE]
3.

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.

Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, Matsumoto M, Mizutani K, Park K, Cahill C, Nishikawa S, Rask-Madsen C, King GL.

Diabetes. 2012 Nov;61(11):2967-79. doi: 10.2337/db11-1824. Epub 2012 Jul 23.

PMID:
22826029
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
[PubMed - indexed for MEDLINE]
5.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
[PubMed - indexed for MEDLINE]
6.

Emerging GLP-1 receptor agonists.

Lund A, Knop FK, Vilsbøll T.

Expert Opin Emerg Drugs. 2011 Dec;16(4):607-18. doi: 10.1517/14728214.2011.616493. Epub 2011 Sep 9. Review.

PMID:
21905764
[PubMed - indexed for MEDLINE]
7.

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.

Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ.

Diabetes. 2009 Sep;58(9):2148-61. doi: 10.2337/db09-0626. Epub 2009 Jun 9.

PMID:
19509017
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.

Mundil D, Cameron-Vendrig A, Husain M.

Diab Vasc Dis Res. 2012 Apr;9(2):95-108. doi: 10.1177/1479164112441526. Review.

PMID:
22496442
[PubMed - indexed for MEDLINE]
Free Article
9.

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.

Breast Cancer Res Treat. 2012 Apr;132(2):449-61. doi: 10.1007/s10549-011-1585-0. Epub 2011 Jun 3.

PMID:
21638053
[PubMed - indexed for MEDLINE]
10.

Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.

Gallwitz B.

Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000. Review.

PMID:
21902291
[PubMed - indexed for MEDLINE]
11.

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N.

Endocrinology. 2008 Feb;149(2):574-9. Epub 2007 Nov 26.

PMID:
18039776
[PubMed - indexed for MEDLINE]
12.

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB.

Endocrinology. 2014 Apr;155(4):1280-90. doi: 10.1210/en.2013-1934. Epub 2014 Jan 27.

PMID:
24467746
[PubMed - indexed for MEDLINE]
13.

Protection of exendin-4 analogue in early experimental diabetic retinopathy.

Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W.

Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):699-706. doi: 10.1007/s00417-008-1004-3. Epub 2008 Dec 16.

PMID:
19084986
[PubMed - indexed for MEDLINE]
14.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.

BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. Review.

PMID:
22236411
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ.

Diabetes. 2009 Apr;58(4):975-83. doi: 10.2337/db08-1193. Epub 2009 Jan 16.

PMID:
19151200
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.

Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ.

J Clin Invest. 2012 Jan 3;122(1):388-402. doi: 10.1172/JCI42497. Epub 2011 Dec 19.

PMID:
22182839
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
[PubMed - indexed for MEDLINE]
Free Article
18.

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.

Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17.

PMID:
19766644
[PubMed - indexed for MEDLINE]
19.

The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.

Maida A, Lovshin JA, Baggio LL, Drucker DJ.

Endocrinology. 2008 Nov;149(11):5670-8. doi: 10.1210/en.2008-0336. Epub 2008 Jul 31.

PMID:
18669601
[PubMed - indexed for MEDLINE]
20.

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M.

Circulation. 2008 May 6;117(18):2340-50. doi: 10.1161/CIRCULATIONAHA.107.739938. Epub 2008 Apr 21. Erratum in: Circulation. 2008 Jul 22;118(4):e81.

PMID:
18427132
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk